UNSPSC 51172300: Antidotes and emetics

This classification denotes agents counteracting or neutralizing the action of poisons.

UNSPSC 51172300 Antidotes and emetics is a Class code encompassing pharmaceutical products and testing services that state and local governments procure for correctional supervision, public health, and employee health benefit programs. Recent solicitations show state and local buyers acquiring drug-testing services (including specimen collection, immunoassay screening, and confirmatory testing), generic pharmaceuticals distributed through wholesaler networks, and related pharmacy benefit support. The issuing-body mix includes county correctional departments, state health and human services agencies, and multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department and the Texas Health and Human Services Commission represent active state and county-level procurement, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinates purchasing across multiple jurisdictions including Oregon.

The code sees recent activity concentrated in Texas and the Upper Midwest. Collin County posted RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and an estimated contract value of $600,000 over two years with optional renewals; the scope covers staffing two testing sites in Plano and McKinney, laboratory screening and confirmation testing for approximately 25,031 annual tests, and electronic result reporting, with awards anticipated August 10, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling preliminary market research before formal competitive solicitation. The Minnesota Department of Administration's Office of State Procurement, through MMCAP, released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers nationwide, with proposals due March 26, 2026 and contract awards effective July 1, 2026.